Source comparison
Follistatin-344 vs MK-677: Which Is Better? | Real Peptides
A 2019 study published in the Journal of Clinical Investigation found that follistatin-344 administration in primates produced measurable increases in lean mass within 14 days by blocking myostatin signaling. The endogenous brake on muscle growth. MK-677, by c
This comparison does not assign a generated winner or score.
- A 2019 study published in the Journal of Clinical Investigation found that follistatin-344 administration in primates produced measurable increases in lean mass within 14 days by blocking myostatin signaling. The endogenous brake on muscle growth. MK-677, by contrast, works through ghrelin receptor activation to pulse growth hormone secretion upward by 60–90% without suppressing endogenous production. These are fundamentally different mechanisms targeting distinct biological objectives, and the question of which is 'better' depends entirely on whether the research goal is localized hypertrophy or systemic anabolic support.
- Our team has guided researchers through peptide selection for years. The gap between informed compound choice and wasted research cycles comes down to understanding mechanism first, then matching it to endpoint.
- What is the core difference between follistatin-344 and MK-677?
- Follistatin-344 is a myostatin inhibitor that directly blocks the negative regulator of skeletal muscle growth, enabling hypertrophy beyond normal genetic limits. MK-677 (ibutamoren) is a ghrelin mimetic that stimulates pulsatile growth hormone release from the pituitary without suppressing natural GH production. The former targets muscle-specific pathways; the latter amplifies systemic anabolic signaling through GH and IGF-1 elevation.
- Most comparison guides frame this as a head-to-head contest, which misses the point entirely. Follistatin-344 doesn't elevate GH or IGF-1 systemically. It removes the molecular brake on muscle fiber proliferation locally. MK-677 doesn't inhibit myostatin. It enhances recovery, nitrogen retention, and metabolic rate through centrally mediated GH pulses. This article covers the distinct mechanisms each compound employs, the dosing protocols used in published research, the timeline for measurable effects, and how to match compound selection to specific research objectives without conflating unrelated pathways.